July 24 (Reuters) – U.S. Food and Drug Administration
scientists on Monday raised concerns that Intellipharmaceutics
International Inc failed to provide data from studies
testing the abuse potential of its long-acting opioid
painkiller.

Read More At Article Source | Article Attribution